Machine Learning to Predict Anti–Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers

Abstract

The model described here shows promise in guiding treatment decisions in clinical practice, based primarily on clinical profiles with additional genetic information.